Compare Palo Alto Networks Inc (PANW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Viatris Inc — how do they compare? Palo Alto Networks Inc trades at $335.38 (market cap $278.85B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Palo Alto Networks Inc is far larger — about 13.6× Viatris Inc's market cap, and Viatris Inc pays a 2.73% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| PANW | VTRS | |
|---|---|---|
Market Cap | $278.85B | $20.50B |
Sector | Technology | Health |
52-Week High | $358.68 | $17.59 |
52-Week Low | $141.67 | $8.74 |
Enterprise Value | $277.81B | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
